Skip to content

Anna Kula-Pacurar

Anna Kula-Pacurar, Ph.D.
Researcher
Laboratory of Virology MCB
E-mail: Anna.Kula-Pacurar [AT] uj.edu.pl

Research interests

  • Molecular dissection of the MATR3/PSF complex in the regulation of HIV-1 posttranscriptional latency: implications for therapy

Grants and Awards
Show More

    • 2019-2023: Characterization of the role MATR3 in HIV latency and reactivation. NCN Sonata Bis (PI: Anna Kula-Pacurar)
    • 2017-2019: Molecular dissection of the MATR3/PSF complex in the regulation of HIV-1 posttranscriptional latency: implications for therapy. POLONEZ program from the National Science Centre co-funded from the EU H2020 Marie Skłodowska-Curie Actions (PI: Anna Kula-Pacurar)
    • 2014-2016: Characterization of the transcriptional activity and epigenetic regulation of the HIV-1 intragenic promoter. Les Amis des Instituts Pasteur à Bruxelles.
    • 2009-2011: Characterization of the PSF/p54nrb/MATR3 pathway of RNA retention in the nucleus. Central European Initiative Research Fellowship Programme (CERES). SP3 People Marie Składowska-Curie Actions.

    • 1.04.2017-untill now: POLONEZ fellowship from the National Science Centre co-funded from the EU H2020 Marie Skłodowska-Curie Actions, Virogenetics group, Malopolska Centre of Biotechnology (MCB), Jagiellonian University, Krakow, Poland.
    • 2013-2016: Post-doctoral fellow at the Universitè Libre de Bruxelles (ULB), the Institute of Molecular Biology and Medicine (IBMM), Gosselies, Belgium.
    • 2009-2012: Post-doctoral fellow at the International Centre for Genetic Engineering and Biotechnology (ICGEB), Triest, Italy.
    • 2009: PhD dissertation, International Centre for Genetic Engineering and Biotechnology (ICGEB), Italy- Open University, United Kindgom.
    • 2005-2009: PhD studies at the International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.
    • 2000-2005: MSc studies at the Faculty of Biology, University of Gdansk, Gdansk, Poland.
    • 2004: Internship at the Biosearch Technologies Chemistry for Genomics, Novato, California, USA.

    1. Kula-Pacurar A, Wadas J, Suder A, Szczepanski A, Milewska A, Ochman M, Stacel T, Pyrc K. (2020). Visualization of SARS-CoV-2 Using Immuno RNA-Fluorescence In Situ Hybridization. JoVE. in press.
    2. Sancineto L, Mangiavacchi F, Dabrowska A, Pacuła A, Obieziurska-Fabisiak M, Scimmi C, Lei Y, Kong J, Zhao Y, dos Santos Machado K, Velasque Werhli A, Ciancaleoni G, Nascimento V, Kula-Pacurar A, João Lenardão E, Yang H, Ścianowski J, Pyrc K, Santi C. Organoselenium mild electrophiles in the inhibition of Mpro and SARS-CoV-2 replication. (2020). ChemRxive. https://doi.org/10.26434/chemrxiv.12994250.v1
    3. Milewska A, Kula-Pacurar A, Wadas J, Suder A, Szczepanski A, Dabrowska A, Owczarek K, Ochman M, Stacel T, Rajfur Z, Sanak M, Labaj P, Branicki W, Pyrc K. Replication of SARS-CoV-2 in human respiratory epithelium. (2020) Journal of Virology. doi: https://doi.org/10.1101/2020.03.20.999029
    4. Fauguenoy S, Robette G*, Kula A*, Vanhulle C, Bouchat S, Delacourt N, Rodari A, Marban C, Schwartz C, Burny A, Rohr O, Van Driessche B and Van Lint C. Repression of Human T-lymphotropic virus type 1 Long Terminal Repeat sense transcription by Sp1 recruitment to novel Sp1 binding sites. Scientific Reports, 2017 Mar 3;7:43221
    5. Gama L, Abreu CM, Shirk EN, Price SL, Li M, Laird GM, Pate KA, Wietgrefe SW, O'connor SL, Pianowski L, Haase AT, Van Lint C, Siliciano RF, Clements JE, Authors D; LRA-SIV Study Group. The LRA-SIV Study Group: Queen S, Bullock BT, Croteau J, Pianowski LF , Gellerup D, Beck SE, Mangus LM, Adams RJ, Perkey K, Rouzioux C, De Wit S, Kula A, Darcis G, Zink C, Mankowski JL. Reactivation of SIV reservoirs in the brain of virally suppressed macaques. AIDS, 2017 Jan 2;31(1):5-14
    6. Darcis G, Bouchat, Kula A, Van Driessche B, Delacourt N, Vanhulle C, Avettand-Fenoel A, De Wit S, Rohr O, Rouzioux C, and Van Lint C. Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir. AIDS, 2017 Jan 14;31(2):181-189
    7. Bouchat S, Delacourt N, Kula A, Darcis G, Corazza F, Gatot J-G, Melard A, Vanhulle C, Van Driessche B, Kabeya K, Pardons, Avettand-Fenoel A, Clumeck N, De Wit S, Rohr O, Rouzioux C, and Van Lint C. Sequential treatment with 5-aza-2’deoxycitidin and Deacetylase Inhibitors Reactivates HIV-1 from Latency. EMBO Mol Med. 2016 Feb 1;8(2):117-38
    8. Darcis G*, Kula A*, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, Van Driessche B, Gatot J-G, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N, Moutschen M, De Wit S, Peterlin M, Rouzioux C, Rohr O and Van Lint C. An In-Depth Comparison of Latency Reversing Drug Combinations in Various in vitro and ex vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol B+JQ1 to Potently Reactivate HIV-1. PLoS Pathog. 2015 Jul 30;11(7):e1005063
    9. Kula A., Gharu L., Marcello A. HIV-1 pre-mRNA commitment to Rev mediated export through PSF and Matrin 3. Virology. 2013 Jan 20;435(2):329-40.
    10. Roesch F, Meziane O, Kula A, Nisole S, Porrot F, Mammano F, Fassati A, Marcello A, Benkirane M, Schwartz O. Hyperthermia stimulates HIV-1 replication. PLoS Pathog. 2012;8(7):e1002792
    11. Kula A., Marcello A. Dynamic post-transcriptional regulation of HIV-1 gene expression. Biology (Basel). 2012 Jul 3;1(2):116-33
    12. Maiuri P, Knezevich A, De Marco A, Mazza D, Kula A, McNally J, Marcello A. Fast transcription rates of RNA polymerase II in human cells. EMBO Rep. 2011 Dec 1;12(12):1280-5
    13. Kula A, Guerra J, Knezevich A, Kleva D, Myers MP, Marcello A. Characterization of the HIV-1 RNA associated proteome identifies Matrin3 as a nuclear cofactor of Rev function. Retrovirology. 2011 Jul 20;8:60
    14. Dieudonné M, Maiuri P, Biancotto C, Knezevich A, Kula A, Lusic M, Marcello A. Transcriptional competence of the integrated HIV-1 provirus at the nuclear periphery. EMBO J. 2009 Aug 5;28(15):2231-43.

    1. P. 416 749. The use of cationially modified dextran for the treatment of infections caused by HSV-1 virus.
    2. P. 409 016: The use of polymers in the treatment and prevention of infections caused by influenza virus.
    3. P. 409 015: The use of polymers in the treatment and prevention of infections caused by human metapneumovirus virus.
    4. PCT/PL2013/050032. Method of RNA viruses identification and its application.
    5. PCT/PL2013/00064. The use of chitosan polymer in the treatment and prevention of infections caused by coronaviruses.
    6. P 401 707. Method for identification of RNA viruses and its application.
    7. P 399 246. Application of chitosan derivatives for treatment and prophylaxis od coronaviral infection.